author-photo

Alexandra Zanin-Zhorov

Weizmann Institute of Science

47

Papers

3079

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

2021 Clinical Immunology
- Alexandra Zanin-Zhorov
- Bruce R. Blazar
Show All
- Source
- Cite
- Save
Citations (0)
ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis

2021
Show All
- Source
- Cite
- Save
Citations (0)
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (19)
Author Correction: Human in vitro-induced regulatory T cells display Dlgh1 dependent and PKC-θ restrained suppressive activity.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (1)
KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) - Pharmacodynamics (PD) and Updated Results

2019 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (3)
ROCK2, but not ROCK1 interacts with phosphorylated STAT3 and co-occupies TH17/TFH gene promoters in TH17-activated human T cells

2018 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (20)
The selective ROCK2 inhibitor KD025 reduces IL‐17 secretion in human peripheral blood mononuclear cells independent of IL‐1 and IL‐6

2018 European Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (5)
KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

2018 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Initial Results of KD025-208: A Phase 2a Open-Label Clinical Trial of KD025 for Steroid-Dependent Chronic Graft Versus Host Disease (cGVHD)

2018 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (2)
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

2017 Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (44)